Author

Hans-Ullrich Ulmer

Observed names: H. U. Ulmer, H.-U. Ulmer

Observed institution: Städtisches Klinikum Karlsruhe

OpenAlex ID: A5111762622

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

2013 · Yasmin Issa-Nummer, Silvia Darb-Esfahani, et al. · PLoS ONE · 232

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

2014 · G. von Minckwitz, S. Loibl, et al. · Annals of Oncology · 139

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

2010 · A. Noske, S. Loibl, et al. · Breast Cancer Research and Treatment · 60

Works count: 3

Citation count: 431

H-index: 3

I10-index: 3